Company news
Medicenna Therapeutics Corp. (TSX:MDNA) news
Medicenna Therapeutics Corp. news releases on 6ix. Latest, May 29, 2020: Medicenna Presents Data on MDNA11, an IL-2 Superkine at ASCO 2020
Press releases — page 2
Medicenna Presents Data on MDNA11, an IL-2 Superkine at ASCO 2020
May 29, 2020
Medicenna Updates Efficacy Results from Phase 2b Recurrent GBM Trial at ASCO 2020
May 29, 2020
Medicenna Announces March 31, 2020 Year-End Results
May 15, 2020
Medicenna Announces Upcoming Presentations at the ASCO Annual Meeting
May 4, 2020
Medicenna Announces Full Exercise of Over-Allotment Option as Part of $40.25 Million Public Offering
April 15, 2020
Medicenna's IL-2 Superkine, MDNA19, Demonstrates Best-in-Class Features in a Non-Human Primate Study
March 25, 2020
Medicenna Announces Closing of Public Offering of $35 Million
March 17, 2020
Medicenna Announces Intention to File Final Short Form Prospectus
March 12, 2020
IIROC Trade Resumption - MDNA
March 4, 2020
Medicenna Announces Pricing of $35 Million Overnight Marketed Offering of Common Shares
March 4, 2020
IIROC Trading Halt - MDNA
March 3, 2020
Medicenna Announces Overnight Marketed Offering of Common Shares
March 3, 2020
Medicenna Reports Third Quarter Fiscal 2020 Financial Results
February 13, 2020
President and CEO of Medicenna Therapeutics Corp., Dr. Fahar Merchant, is Featured on The Stock Day Podcast
January 21, 2020
Medicenna Reports Compelling Results from Recurrent Glioblastoma Trial When Compared to an Eligibility-Matched Control Arm
January 13, 2020
Medicenna Receives $1.3 Million Through Early Warrant Exercises
January 8, 2020
Medicenna Presents Additional Encouraging Phase 2b Clinical Data at the Inaugural Glioblastoma Drug Development Annual Summit
December 12, 2019
Medicenna Announces Presentation of the MDNA55 Clinical Trial at the Inaugural Glioblastoma Drug Development Annual Summit
December 9, 2019
Medicenna Reports Promising Efficacy in Phase 2b MDNA55 Clinical Trial at the Society for Neuro-Oncology Annual Meeting
November 25, 2019
Medicenna Reports Improved Drug Distribution of MDNA55 with Novel Delivery Technology in Phase 2b Recurrent Glioblastoma Clinical Trial
November 21, 2019
Medicenna To Host Key Opinion Leader Call Focused on Latest MDNA55 Recurrent Glioblastoma Phase 2b Clinical Study Results
November 20, 2019
Medicenna to Host a Key Opinion Leader Symposium on MDNA55 for Treatment of Recurrent Glioblastoma
November 18, 2019
Medicenna Announces Presentations on MDNA55 Recurrent Glioblastoma Clinical Trial at the Annual Meeting of the Society of Neuro-Oncology
November 14, 2019
Medicenna Reports Second Quarter Fiscal 2020 Financial Results
November 5, 2019
Medicenna Announces Closing of Public Offering of $6,900,000
October 17, 2019
Medicenna Announces Filing of Final Short Form Prospectus
October 11, 2019
Medicenna Announces Pricing of Marketed Offering of Units
October 2, 2019
Medicenna Announces Offering of Units
October 1, 2019
Medicenna Presented Promising Preclinical Results from its IL-2 Superkine Platform at the 5th Annual International Cancer Immunotherapy Conference
September 30, 2019
Nature Communications Publishes Studies on Medicenna's IL-2 Superkine Platform
September 26, 2019
Medicenna Presents Promising Update from its MDNA55 Clinical Trial in Recurrent Glioblastoma at the Targeting Innate Immunity Congress
September 25, 2019
Medicenna Strengthens Board of Directors by Appointment of Seasoned Biopharma Executive Ms. Karen Dawes
September 24, 2019
Medicenna to Present MDNA19 Pre-clinical Update at the 5th Annual International Cancer Immunotherapy Conference
September 17, 2019
Medicenna to Present Latest Data from the MDNA55 Clinical Trial in Recurrent Glioblastoma at the Targeting Innate Immunity Congress
September 12, 2019
Medicenna Reports First Quarter Fiscal 2020 Financial Results
August 9, 2019
Medicenna Selects its Lead Immuno-Oncology Clinical Candidate, MDNA19, from its IL-2 Superkine Platform
July 31, 2019
Medicenna Receives US $1.9 Million Non-Dilutive Grant Payment
July 9, 2019
MDNA55 Shows Promising Results in Models of Ovarian Cancer
June 26, 2019
Medicenna Announces March 31, 2019 Year-End Results
June 25, 2019
Medicenna Presents New Preclinical Results For its IL-2 Superkine Platform, MDNA109
June 20, 2019
Medicenna to Present at Raymond James Life Sciences and MedTech Conference
June 19, 2019
Medicenna Presents Preliminary Top-Line Clinical Results from their Phase 2b Trial of MDNA55 in Recurrent Glioblastoma
June 18, 2019
Medicenna To Host Key Opinion Leader Call Focused on MDNA55 Recurrent Glioblastoma Program and Preliminary Top-Line Results
June 13, 2019
Medicenna To Present Preliminary Top-Line Results on MDNA55 at the Immuno-Oncology Pharma Congress
June 5, 2019
Medicenna Presents Clinical Validation of the IL4 Receptor as a Biomarker for MDNA55 in Recurrent Glioblastoma
June 3, 2019
Medicenna to Present at the 9th Annual LD Micro Invitational
May 30, 2019
Medicenna Announces Upcoming Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting
May 16, 2019
Medicenna Receives Non-Dilutive Grant Payment
May 1, 2019
Medicenna Announces Completion of Enrolment in MDNA55 Phase 2b Recurrent Glioblastoma Clinical Study
April 30, 2019
Medicenna to Present at Bloom Burton & Co. Healthcare Investor Conference 2019
April 23, 2019